The rapid pace of cancer research regularly uncovers new oncogenic drivers, and even when a reliable molecular test exists, positive results are meaningful only when there is a corresponding therapeutic intervention. This is where Ignyta is different: our Rx/Dx platform provides a seamless match between drug candidates and CLIA-certified (and CAP, HIPAA, and QSR compliant) diagnostic tests to generate clear, actionable results for your patients.
But just how does Ignyta’s Rx/Dx approach translate to better patient care and outcomes?
Ignyta’s Rx Capability and Our Precision Medicine Pipeline
By illuminating the exact molecular alterations that are driving patients’ individual cancers, we can match patients with molecularly targeted treatments specifically aimed at stopping their disease in its tracks.
Ignyta’s R&D team has a proven record of developing drugs that work in disease models and in real life. Here’s a snapshot of current Phase I and Phase II data for our flagship drug candidate, entrectinib: